NEW YORK, Dec. 10, 2015
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of
investors of Liberator Medical Holdings, Inc. ("Liberator Medical"
or the "Company") (NYSE: LBMH) (ISIN: US5312L1089) (CUSIP:
5312L108) concerning the proposed acquisition of Liberator by C.R.
Bard, Inc.
Liberator Medical shareholders seeking more information about
this acquisition are advised to contact Robert Willoughby at rswilloughby@pomlaw.com or
212-661-1100 or 888-476-6529, ext. 9980.
The investigation concerns whether the Liberator Medical
directors are breaching their fiduciary duties by failing to
adequately shop the Company and maximize shareholder value.
Under the terms of the proposed transaction, Liberator Medical
shareholders will receive $3.35 per
shares in cash for each Liberator Medical share. However, an
analyst recently set a price target of $8.00 per share for Liberator Medical,
additionally, EBITDA, EBIT, and Total Revenue are below the
averages of comparable transactions, according to a
Bloomberg analysis.
Pomerantz LLP, with offices in New
York, Chicago, Florida, and Los
Angeles, is acknowledged as one of the premier firms in the
areas of corporate, securities, and antitrust class litigation.
Founded by the late Abraham L.
Pomerantz, known as the dean of the class action bar, the
Pomerantz LLP pioneered the field of securities class actions.
Today, more than 75 years later, the Pomerantz LLP continues in the
tradition he established, fighting for the rights of the victims of
securities fraud, breaches of fiduciary duty, and corporate
misconduct. The Firm has recovered numerous multimillion-dollar
damages awards on behalf of defrauded investors. See
www.pomerantzlaw.com.
CONTACT:
Robert
Willoughby
Pomerantz LLP
212-661-1100 ext. 9980
rswilloughby@pomlaw.com
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/shareholder-alert-pomerantz-llp-investigates-claims-that-the-merger-may-not-be-in-the-best-interest-of-investors-of-liberator-medical-holdings-inc--lbmh-300191513.html
SOURCE Pomerantz LLP